Shots:
- AstraZeneca reported data from replicate P-III (OBERON & TITANIA) trials assessing tozorakimab (300mg, Q4W) vs PBO over 52wks. on top of inhaled therapy in 2,306 adults with symptomatic COPD & prior exacerbations
- The trial met its 1EP, reducing annualised rates of mod. to sev. COPD exacerbations in former smokers & the overall population, incl. patients regardless of eosinophil levels, smoking status, or lung function severity; data to be presented in a future conference
- Tozorakimab is being assessed in additional P-III (PROSPERO & MIRANDA) trials for COPD, a P-III (TILIA) trial for severe viral lower respiratory tract disease & a P-II (Umbriel) trial in asthma
Ref: AstraZeneca| Image: AstraZeneca | Press Release
Related News: AstraZeneca Reports P-III (LOGOS & KALOS) Trial Findings on Breztri Aerosphere for Uncontrolled Asthma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
